A Phase 1 Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of HMI-203 in ERT-Treated Adults With Mucopolysaccharidosis Type II (MPS II) (juMPStart Trial)
Latest Information Update: 30 Aug 2023
At a glance
- Drugs HMI-203 (Primary)
- Indications Mucopolysaccharidosis II
- Focus Adverse reactions; Therapeutic Use
- Acronyms juMPStart Trial
- Sponsors Homology Medicines
- 24 Aug 2023 Status changed from recruiting to withdrawn prior to enrolment.
- 15 Mar 2023 According to a Homology Medicines media release, design of this trial will be presented during the ACMG Annual Clinical Genetics Meeting 2023.
- 05 Jan 2023 Planned End Date changed from 1 Oct 2028 to 1 Jan 2029.